BackgroundTumor suppressor WOX1 (also named WWOX or FOR) is known to participate in
neuronal apoptosis in vivo. Here, we investigated the
functional role of WOX1 and transcription factors in the delayed loss of
axotomized neurons in dorsal root ganglia (DRG) in rats.Methodology/Principal FindingsSciatic nerve transection in rats rapidly induced JNK1 activation and
upregulation of mRNA and protein expression of WOX1 in the injured DRG
neurons in 30 min. Accumulation of p-WOX1, p-JNK1, p-CREB, p-c-Jun,
NF-κB and ATF3 in the nuclei of injured neurons took place within
hours or the first week of injury. At the second month, dramatic nuclear
accumulation of WOX1 with CREB (>65% neurons) and
NF-κB (40–65%) occurred essentially in small
DRG neurons, followed by apoptosis at later months. WOX1 physically
interacted with CREB most strongly in the nuclei as determined by FRET
analysis. Immunoelectron microscopy revealed the complex formation of p-WOX1
with p-CREB and p-c-Jun in vivo. WOX1 blocked the
prosurvival CREB-, CRE-, and AP-1-mediated promoter activation in
vitro. In contrast, WOX1 enhanced promoter activation governed
by c-Jun, Elk-1 and NF-κB. WOX1 directly activated
NF-κB-regulated promoter via its WW domains. Smad4 and p53 were not
involved in the delayed loss of small DRG neurons.Conclusions/SignificanceRapid activation of JNK1 and WOX1 during the acute phase of injury is
critical in determining neuronal survival or death, as both proteins
functionally antagonize. In the chronic phase, concurrent activation of
WOX1, CREB, and NF-κB occurs in small neurons just prior to
apoptosis. Likely in vivo interactions are: 1) WOX1
inhibits the neuroprotective CREB, which leads to eventual neuronal death,
and 2) WOX1 enhances NF-κB promoter activation (which turns to be
proapoptotic). Evidently, WOX1 is the potential target for drug intervention
in mitigating symptoms associated with neuronal injury.
Purpose:We investigated the role of candidate tumor suppressor and proapoptotic WOX1 (also named WWOX, FOR, or WWOXv1) in UVB-induced apoptosis and formation of cutaneous squamous cell carcinomas (SCC). Experimental Design: Expression of WOX1and family proteins (WWOX) in human primary cutaneous SCCs was examined by immunohistochemistry, in situ hybridization, and reverse transcription-PCR. UVB irradiation^induced WOX1 activation (Tyr 33 phosphorylation and nuclear translocation), apoptosis, and cutaneous SCC formation were examined both in vitro and in vivo. Results: Up-regulation of human WOX1, isoform WOX2, and Tyr 33 phosphorylation occurred during normal keratinocyte differentiation before cornification and death. Interestingly, significant reduction of these proteins and Tyr 33 phosphorylation was observed in nonmetastatic and metastatic cutaneous SCCs (P < 0.001), but without down-regulation of WWOX mRNA (P > 0.05 versus normal controls), indicating a translational blockade of WWOX mRNA to protein.During acute exposure of hairless mice to UVB, WOX1was up-regulated and activated in epidermal cells in 24 hours. In parallel with the clinical findings in humans, chronic UVB-treated mice developed cutaneous SCCs in 3 months, with significant reduction of WOX1 and Tyr 33 phosphorylation and, again, without down-regulation of WWOX mRNA. Human SCC-25 and HaCaT cells were transfected with small interfering RNA^targeting WOX1 and shown to resist UVBinduced WOX1 expression, activation, and apoptosis. Conclusions: WOX1 is essential for UVB-induced apoptosis and likely to be involved in the terminal differentiation of normal keratinocytes. During UVB-induced cutaneous SCC, epidermal cells have apparently prevented the apoptotic pressure from overexpressed WOX1 by shutting down the translation machinery for WWOX mRNA.
Previous studies have shown that cannabinoids have anti-inflammatory and immune-modulating effects, but the precise mechanisms of action remain to be elucidated. In this study, we investigated the effect of JWH 133, a selective agonist for cannabinoid receptor 2, the main receptor expressed on immune cells, in a model of autoimmune disease, experimental autoimmune uveoretinitis (EAU). JWH 133 suppressed EAU in a dose-dependent manner (0.015-15 mg/kg), and the suppressive effect could be achieved in the disease-induction stage and the effector stage. Leukocytes from mice, which had been treated with JWH 133, had diminished responses to retinal peptide and mitogen Con A stimulation in vitro. In vivo JWH 133 treatment also abrogated leukocyte cytokine/chemokine production. Further in vitro studies indicated that JWH 133 down-regulated the TLR4 via Myd88 signal transduction, which may be responsible for its moderate, suppressive effect on antigen presentation. In vivo JWH 133 treatment (1 mg/kg) also suppressed leukocyte trafficking (rolling and infiltration) in inflamed retina as a result of an effect on reducing adhesion molecules CD162 (P-selectin glycoprotein ligand 1) and CD11a (LFA-1) expression on T cells. In conclusion, the cannabinoid agonist JWH 133 has a high in vivo, anti-inflammatory property and may exert its effect via inhibiting the activation and function of autoreactive T cells and preventing leukocyte trafficking into the inflamed tissue.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.